16758-34-2Relevant articles and documents
Synthesis of Glycosyl Fluorides by Photochemical Fluorination with Sulfur(VI) Hexafluoride
Bannykh, Anton,Khomutnyk, Yaroslav,Kim, Sungjin,Nagorny, Pavel
supporting information, p. 190 - 194 (2021/01/13)
This study describes a new convenient method for the photocatalytic generation of glycosyl fluorides using sulfur(VI) hexafluoride as an inexpensive and safe fluorinating agent and 4,4′-dimethoxybenzophenone as a readily available organic photocatalyst. This mild method was employed to generate 16 different glycosyl fluorides, including the substrates with acid and base labile functionalities, in yields of 43%-97%, and it was applied in continuous flow to accomplish fluorination on an 7.7 g scale and 93% yield.
Rhamnogalacturonan II: Chemical Synthesis of a Substructure Including α-2,3-Linked Kdo**
Mancuso, Enzo,Romanò, Cecilia,Trattnig, Nino,Gritsch, Philipp,Kosma, Paul,Clausen, Mads H.
, p. 7099 - 7102 (2021/04/19)
The synthesis of a fully deprotected Kdo-containing rhamnogalacturonan II pentasaccharide is described. The strategy relies on the preparation of a suitably protected homogalacturonan tetrasaccharide backbone, through a post-glycosylation oxidation approach, and its stereoselective glycosylation with a Kdo fluoride donor.
Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity
Recio, Rocío,Lerena, Patricia,Pozo, Esther,Calderón-Monta?o, José Manuel,Burgos-Morón, Estefanía,López-Lázaro, Miguel,Valdivia, Victoria,Pernia Leal, Manuel,Mouillac, Bernard,Organero, Juan ángel,Khiar, Noureddine,Fernández, Inmaculada
, p. 10350 - 10370 (2021/07/28)
NK1R antagonists, investigated for the treatment of several pathologies, have shown encouraging results in the treatment of several cancers. In the present study, we report on the synthesis of carbohydrate-based NK1R antagonists and their evaluation as anticancer agents against a wide range of cancer cells. All of the prepared compounds, derived from either-arabinose, have shown high affinity and NK1R antagonistic activity with a broad-spectrum anticancer activity and an important selectivity, comparable to Cisplatin. This strategy has allowed us to identify the galactosyl derivative 14α , as an interesting hit exhibiting significant NK1R antagonist effect (kinact0.209 ± 0.103 μM) and high binding affinity for NK1R (IC50= 50.4 nM,Ki= 22.4 nM by measuring the displacement of [125I] SP from NK1R). Interestingly, this galactosyl derivative has shown marked selective cytotoxic activity against 12 different types of cancer cell lines.